NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Berenberg analyst Luisa Hector lowered the firm’s price target on Merck (MRK) to $115 from $125 and keeps a Buy rating on the shares. Merck ...

Glancy Prongay & Murray LLP reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the class action filed on ...

COLORADO SPRINGS—Sierra Space has announced pharmaceutical giant Merck as its first commercial rideshare partner for the ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...